Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

NCT06393335 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia
Non-hodgkin Lymphoma

Interventions

DRUG: Metabolically Armed CD19 CAR-T cells

Sponsor

The Children's Hospital of Zhejiang University School of Medicine

Collaborators

[object Object]